MASLD/MetALD and mortality in individuals with any cardio-metabolic risk factor: A population-based study with 26.7 years of follow-up.
Min Sun KwakHyun-Seok KimZhenghui Gordon JiangYee Hui YeoHirsh D TrivediMazen NoureddinJu Dong YangPublished in: Hepatology (Baltimore, Md.) (2024)
In individuals with CMRF, the presence of steatotic liver disease (MASLD) alone did not increase the risk of mortality, except in cases with more alcohol consumption (MetALD). Therefore controlling metabolic risk factors and reducing alcohol consumption in people with MASLD or MetALD will be crucial steps to improve long-term health outcomes.